Models of reactive oxygen species in cancer

Drug Discovery Today: Disease Models

Volumn 4, Issue 2, 2007, Pages 67-73

  Lu, Weiqin ^a,b   Ogasawara, Marcia A ^a,b   Huang, Peng ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; MANGANESE SUPEROXIDE DISMUTASE; MYC PROTEIN; PROTEIN P53; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE 3; UNCLASSIFIED DRUG;

BIOLOGICAL MODEL; CANCER CELL; CANCER RISK; CELL DEATH; CELL PROLIFERATION; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; GENETIC STABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHENOTYPE; REVIEW; TRANSGENIC MOUSE;

EID: 40849131132     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2007.10.005     Document Type: Review

References (44)

1. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82 (2002) 47-95
2. Irani K., et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275 (1997) 1649-1652
3. Serrano M., et al. Oncogenic Ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
4. Kemp C.J., et al. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74 (1993) 813-822
5. Braig M., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
6. Liu J., et al. A genetically defined model for human ovarian cancer. Cancer Res. 64 (2004) 1655-1663
7. Young T.W., et al. Activation of antioxidant pathways in Ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res. 64 (2004) 4577-4584
8. Trachootham D., et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10 (2006) 241-252
9. Daley G.Q., and Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 9312-9316
10. Sattler M., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 275 (2000) 24273-24278
11. Klucher K.M., et al. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 91 (1998) 3927-3934
12. Nowicki M.O., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104 (2004) 3746-3753
13. Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell Biol. 19 (1999) 1-11
14. Felsher D.W., and Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3940-3944
15. Vafa O., et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9 (2002) 1031-1044
16. Ray S., et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 66 (2006) 6598-6605
17. Bunz F., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
18. Bensaad K., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 (2006) 107-120
19. Matoba S., et al. p53 regulates mitochondrial respiration. Science 312 (2006) 1650-1653
20. Green D.R., and Chipuk J.E. p53 and metabolism: inside the TIGAR. Cell 126 (2006) 30-32
21. Sablina A.A., et al. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005) 1306-1313
22. Reaume A.G., et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat. Genet. 13 (1996) 43-47
23. Huang T.T., et al. Superoxide-mediated cytotoxicity in superoxide dismutase-deficient fetal fibroblasts. Arch. Biochem. Biophys. 344 (1997) 424-432
24. Elchuri S., et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene 24 (2005) 367-380
25. Muller F.L., et al. Absence of CuZn superoxide dismutase leads to elevated oxidative stress and acceleration of age-dependent skeletal muscle atrophy. Free Radic. Biol. Med. 40 (2006) 1993-2004
26. Didion S.P., et al. Heterozygous CuZn superoxide dismutase deficiency produces a vascular phenotype with aging. Hypertension 48 (2006) 1072-1079
27. Bogdanov M.B., et al. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J. Neurochem. 71 (1998) 1321-1324
28. Liu R., et al. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann. Neurol. 44 (1998) 763-770
29. Poon H.F., et al. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 39 (2005) 453-462
30. Li Y., et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat. Genet. 11 (1995) 376-381
31. Lebovitz R.M., et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9782-9787
32. Van Remmen H., et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol. Genomics 16 (2003) 29-37
33. Carlsson L.M., et al. Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 6264-6268
34. Kim S.H., et al. Overexpression of extracellular superoxide dismutase (EC-SOD) in mouse skin plays a protective role in DMBA/TPA-induced tumor formation. Oncol. Res. 15 (2005) 333-341
35. Schriner S.E., et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308 (2005) 1909-1911
36. Cheng W.H., et al. Cellular glutathione peroxidase knockout mice express normal levels of selenium-dependent plasma and phospholipid hydroperoxide glutathione peroxidases in various tissues. J. Nutr. 127 (1997) 1445-1450
37. Ho Y.S., et al. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J. Biol. Chem. 272 (1997) 16644-16651
38. Yoshida T., et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J. Mol. Cell Cardiol. 28 (1996) 1759-1767
39. Fu Y., et al. Comparative impacts of glutathione peroxidase-1 gene knockout on oxidative stress induced by reactive oxygen and nitrogen species in mouse hepatocytes. Biochem. J. 359 Pt 3 (2001) 687-695
40. McClung J.P., et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8852-8857
41. Lu Y.P., et al. Enhanced skin carcinogenesis in transgenic mice with high expression of glutathione peroxidase or both glutathione peroxidase and superoxide dismutase. Cancer Res. 57 (1997) 1468-1474
42. Garcia-Cao I., et al. Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21 (2002) 6225-6235
43. Matheu A., et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev. 18 (2004) 2736-2746
44. Matheu A., et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448 (2007) 375-379